Creative Planning Makes New Investment in Regulus Therapeutics Inc. (NASDAQ:RGLS)

Creative Planning bought a new position in Regulus Therapeutics Inc. (NASDAQ:RGLS) in the third quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund bought 16,466 shares of the biopharmaceutical company’s stock, valued at approximately $26,000.

A number of other institutional investors also recently modified their holdings of the stock. SG Americas Securities LLC bought a new position in shares of Regulus Therapeutics in the third quarter worth about $33,000. Renaissance Technologies LLC grew its position in shares of Regulus Therapeutics by 56.4% during the 2nd quarter. Renaissance Technologies LLC now owns 118,100 shares of the biopharmaceutical company’s stock worth $211,000 after buying an additional 42,600 shares during the period. Rhumbline Advisers acquired a new stake in shares of Regulus Therapeutics during the 2nd quarter worth approximately $136,000. Bank of New York Mellon Corp acquired a new stake in shares of Regulus Therapeutics during the 2nd quarter worth approximately $352,000. Finally, Opaleye Management Inc. acquired a new stake in shares of Regulus Therapeutics during the 1st quarter worth approximately $490,000. 92.38% of the stock is owned by institutional investors.

Regulus Therapeutics Stock Performance

Shares of NASDAQ RGLS opened at $1.50 on Thursday. The stock has a market cap of $98.25 million, a P/E ratio of -1.40 and a beta of 1.63. The firm has a 50 day moving average price of $1.55 and a 200 day moving average price of $1.81. Regulus Therapeutics Inc. has a 52-week low of $1.08 and a 52-week high of $3.79.

Regulus Therapeutics (NASDAQ:RGLS) last issued its quarterly earnings data on Thursday, November 7th. The biopharmaceutical company reported ($0.21) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.18) by ($0.03). Analysts predict that Regulus Therapeutics Inc. will post -0.83 earnings per share for the current fiscal year.

Analysts Set New Price Targets

RGLS has been the subject of several analyst reports. StockNews.com upgraded shares of Regulus Therapeutics to a “sell” rating in a research report on Tuesday, September 17th. Oppenheimer reiterated an “outperform” rating and set a $7.00 price target on shares of Regulus Therapeutics in a research report on Wednesday, August 14th. Finally, HC Wainwright reiterated a “buy” rating and set a $10.00 price target on shares of Regulus Therapeutics in a research report on Monday. One research analyst has rated the stock with a sell rating, one has given a hold rating and five have assigned a buy rating to the company. Based on data from MarketBeat.com, Regulus Therapeutics presently has a consensus rating of “Moderate Buy” and an average target price of $10.80.

Regulus Therapeutics Profile

Regulus Therapeutics Inc, a clinical-stage biopharmaceutical company, focuses on discovery and development of drugs that targets microRNAs to treat a range of diseases in the United States. Its product candidates include RGLS8429, an anti-miR next generation oligonucleotide targeting miR-17, which is in Phase 1b clinical trial for the treatment of autosomal dominant polycystic kidney disease.